Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 3,750 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $78.89, for a total value of $295,837.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kevin Charles Gorman also recently made the following trade(s):
- On Tuesday, February 6th, Kevin Charles Gorman sold 105,983 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $80.25, for a total transaction of $8,505,135.75.
Shares of Neurocrine Biosciences, Inc. (NBIX) traded up $2.89 during mid-day trading on Monday, reaching $82.17. The company’s stock had a trading volume of 765,665 shares, compared to its average volume of 1,020,000. Neurocrine Biosciences, Inc. has a 1-year low of $39.21 and a 1-year high of $91.82. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. The stock has a market cap of $7,270.00, a price-to-earnings ratio of -37.01, a PEG ratio of 13.14 and a beta of 0.26.
Hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company increased its stake in Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after buying an additional 193 shares in the last quarter. Crow Point Partners LLC purchased a new stake in Neurocrine Biosciences in the 4th quarter worth $145,000. American International Group Inc. purchased a new stake in Neurocrine Biosciences in the 4th quarter worth $161,000. M&T Bank Corp bought a new position in shares of Neurocrine Biosciences during the 4th quarter valued at about $202,000. Finally, Mission Wealth Management LP bought a new position in shares of Neurocrine Biosciences during the 4th quarter valued at about $204,000.
A number of equities research analysts have weighed in on NBIX shares. Robert W. Baird reiterated a “buy” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. Needham & Company LLC boosted their target price on shares of Neurocrine Biosciences to $95.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. Piper Jaffray Companies restated a “buy” rating and issued a $76.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. Oppenheimer set a $95.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Monday, January 15th. Finally, Deutsche Bank restated a “buy” rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. One analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $84.13.
ILLEGAL ACTIVITY WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/12/insider-selling-neurocrine-biosciences-inc-nbix-ceo-sells-295837-50-in-stock.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.